Statera Biopharma is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Co.'s proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia. Co.'s product candidate in this field is entolimod, an immune-stimulatory agent, which Co. is developing as a radiation countermeasure and other indications in radiation oncology. We show 6 historical shares outstanding datapoints in our STAB shares outstanding history coverage, used to compute STAB market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing STAB market cap history over the course of time is important for investors
interested in comparing STAB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of STAB versus a peer is one thing; comparing
STAB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like STAB can fluctuate over the course of history.
With this page we aim to empower investors researching STAB by allowing them to research the STAB market cap history. |
Free STAB Email Alerts:
Video: The Importance of Market Cap
